Talquetamab and Its Effect on Relapsed and Refractory Multiple Myeloma.
Relapsed and refractory multiple myeloma (RRMM) remains a challenging condition despite many advances in immunotherapies. Talquetamab demonstrated a high overall response rate of approximately 70%, including in patients that are previously treated with T-cell therapies.
Relapsed and refractory multiple myeloma (RRMM) remains a challenging condition despite many advances in immunotherapies. Talquetamab demonstrated a high overall response rate of approximately 70%, including in patients that are previously treated with T-cell therapies.
What the study was
- Study design
- Observational or experimental study
- Population
- Human participants; details are provided in the abstract.
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Annals of African medicine
Why it surfaced
Retained as a 9/10 high-priority candidate for Novel therapeutics: immunotherapy, CAR-T, targeted therapy; PubMed metadata and abstract were assessed conservatively.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.